Stocks and Investing
Stocks and Investing
Fri, January 26, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Hartaj Singh Maintained (SMMT) at Buy with Increased Target to $30 on, Jan 26th, 2018
Hartaj Singh of Oppenheimer, Maintained "Summit Therapeutics Inc." (SMMT) at Buy with Increased Target from $24 to $30 on, Jan 26th, 2018.
Hartaj has made no other calls on SMMT in the last 4 months.
There is 1 other peer that has a rating on SMMT. Out of the 1 peers that are also analyzing SMMT, 0 agree with Hartaj's Rating of Hold.
This is the rating of the analyst that currently disagrees with Hartaj
- Carol Werther of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $16 on, Friday, December 1st, 2017
Contributing Sources